Breakthrough EU approval for Dupixent offers new hope for children with eosinophilic esophagitis

Pallavi Madhiraju- November 8, 2024 0

The European Medicines Agency (EMA) has granted approval for Dupixent, a therapy developed by Sanofi and Regeneron, to treat eosinophilic esophagitis (EoE) in children as ... Read More

Eupraxia Pharmaceuticals announces promising results for EP-104GI in eosinophilic esophagitis trial

Pallavi Madhiraju- May 22, 2024 0

Eupraxia Pharmaceuticals Inc., listed on both TSX and NASDAQ under the ticker EPRX, has revealed encouraging results from its ongoing Phase 1b/2a RESOLVE trial. The ... Read More

Sanofi, Regeneron get Dupixent EC approval for eosinophilic esophagitis

Raghuram Kadari- February 1, 2023 0

French pharmaceutical company Sanofi and Regeneron, an American biotechnology company, have received the approval of the European Commission (EC) to market their Dupixent (dupilumab) injection ... Read More

FDA refuses to approve AstraZeneca’s sBLA for Fasenra in CRSwNP

pallavi123- March 19, 2022 0

The US Food and Drug Administration (FDA) has refused to approve the supplemental biologics license application (sBLA) of AstraZeneca’s asthma drug Fasenra (benralizumab) for the ... Read More

Dupixent delivers positive results in eosinophilic esophagitis trial

pharmanewsdaily- May 24, 2020 0

Regeneron Pharmaceuticals and Sanofi said that their co-developed eczema drug Dupixent (dupilumab) has met the co-primary endpoints of Part A of a phase 3 trial ... Read More